Optic Neuritis Clinical Trial
Official title:
Study of the VIsual Pathways MODEL for a Better Understanding of Neurodegeneration in Inflammatory and Demyelinating Disorders of Central Nervous System
In neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disorders (MOGAD), neuronal degeneration is the consequence of inflammatory and demyelinating lesions in the brain, optic nerve and spinal cord. Both white and grey matter are systematically affected. Lesions of the perivascular spaces containing cerebrospinal fluid (CSF) and meningeal inflammation seem to play an important role in the pathophysiology of these neuroinflammatory diseases. Currently, the interrelation of all these aspects is not clearly established in the pathophysiology of these diseases. In order to better understand the mechanisms that lead to and underlie the clinical disability of patients with these diseases, we need in vivo study models that allow the in-depth study of the neurodegenerative process and the identification of its causes. In this perspective, we make the hypothesis that the visual pathways model is very relevant to measure neuro-axonal loss and to explore the different mechanisms involved in neurodegeneration during MS and other CNS demyelinating diseases. Researchers have at their disposal many tools that allow them to analyse and quantify the neurodegenerative process in a reproducible and very precise manner from a structural and functional point of view, while taking into account possible vascular involvement (MRI, optical coherence tomography - angiography, etc…).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Unknown status |
NCT00261326 -
Simvastatin Treatment of Patients With Acute Optic Neuritis
|
Phase 3 | |
| Active, not recruiting |
NCT03963310 -
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
|
||
| Recruiting |
NCT03586557 -
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
|
N/A | |
| Terminated |
NCT04131764 -
Diagnosis of ON With or Without MS or NMOSD
|
||
| Not yet recruiting |
NCT06453694 -
Efgartigimod for the Treatment of Acute Optic Neuritis
|
Phase 2 | |
| Completed |
NCT01962571 -
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
|
Phase 3 | |
| Recruiting |
NCT03302585 -
High-Dose Vitamin D Induction in Optic Neuritis
|
Phase 2 | |
| Recruiting |
NCT02886377 -
The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
|
N/A | |
| Completed |
NCT01987167 -
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
|
Early Phase 1 | |
| Completed |
NCT01451593 -
Neuroprotection With Phenytoin in Optic Neuritis
|
Phase 2 | |
| Completed |
NCT03630497 -
BN201 SAD MAD Study in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01337986 -
Ampyra for Optic Neuritis in Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Completed |
NCT01274702 -
Visual Reconstitution Therapy After Optic Neuritis
|
Phase 2 | |
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Withdrawn |
NCT00037115 -
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
|
Phase 4 | |
| Not yet recruiting |
NCT06389968 -
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT04257734 -
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
|
||
| Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
| Completed |
NCT02939937 -
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
|
Phase 2 | |
| Recruiting |
NCT04148781 -
Fampridine-SR and Optic Neuritis Recovery
|
Early Phase 1 |